

# Review of: "Targeting Cancer Cell Signaling Using Precision Oncology Towards a Holistic Approach to Cancer Therapeutics"

Franz Rödel<sup>1</sup>

<sup>1</sup> Goethe University Frankfurt

Potential competing interests: No potential competing interests to declare.

In the manuscript, author Kunar aimed to comprehensively review on multiple aspects of molecular cancer development, progression and targeting treatment. In principle, the topic of the review is interesting and of clinical relevance. There are, however, some major shortcomings as given successive that need to be considered. In the light of these drawbacks, the manuscript does not reach a level to be acceptable for publication in Qeios in its current form.

Major points of improvements:

1. There are several redundancies in the manuscript. The review should be shortened excluding well described textbook knowledge in biochemical pathways. By contrast, some pathways including apoptosis and epithelial-to-mesenchymal transition should briefly be included.
2. Table 1 is of low informative content and highly restricted to a few tumor entities. In addition, table 2 mainly covers an incomplete enumeration of tyrosine kinase inhibitors targeting approaches, but fails to include additional drugs like mitotic and DNA damage repair inhibitors.
3. Although provided with permission from Elsevier, figure 1 and figure 4 are direct copies from the well-known review by Hanahan and Weinberg. To the reviewer's opinion, a well performed manuscript should include own designed novel figures.
4. Paragraph 7: "The Cancer Genome Atlas (TCGA) Program and Related Cancer Initiatives" covers a timely and important topic but is not within the scope of the review article. This paragraph should substantially be shortened or omitted.